The latest price target for UroGen Pharma (NASDAQ:URGN) was reported by HC Wainwright & Co. on February 25, 2025. The analyst firm set a price target for $64.00 expecting URGN to rise to within 12 months (a possible 529.30% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for UroGen Pharma (NASDAQ:URGN) was provided by HC Wainwright & Co., and UroGen Pharma reiterated their buy rating.

There is no last upgrade for UroGen Pharma

The last downgrade for UroGen Pharma Ltd happened on February 8, 2023 when Jefferies changed their price target from $35 to $10 for UroGen Pharma Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on February 25, 2025 so you should expect the next rating to be made available sometime around February 25, 2026.

While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a reiterated with a price target of $64.00 to $64.00. The current price UroGen Pharma (URGN) is trading at is $10.17, which is out of the analyst’s predicted range.